What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in hospitalisations due to diarrhoea (low certainty).

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  RR 1.55 [0.86, 2.79]
  1 study · 534 participants
  Low

Intervention not reported

The intervention showed no clear difference in respiratory infections hospital admission for pneumonia/empyema (low certainty).

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  RR 0.84 [0.57, 1.24]
  1 study · 534 participants
  Low

Intervention not reported

The intervention showed no clear difference in hospitalisations for diarrhoea number of episodes per number (low certainty).

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  RR 0.25 [0.05, 1.15]
  1 study · 194 participants
  Low

Intervention not reported

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 267 participants
  Very low

Intervention not reported

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 209 participants
  Low

Intervention not reported

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 239 participants
  Very low

Intervention not reported

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 267 participants
  Low

Intervention not reported

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2966 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection 2010 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

d4T vs AZT

It is very uncertain whether d4T changes mortality compared with AZT (very low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 1.36 [0.34, 5.42]
  6 studies · 1179 participants
  Very low

d4T vs AZT

d4T showed no clear difference in clinical progression compared with AZT (low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 0.78 [0.28, 2.13]
  7 studies · 719 participants
  Low

d4T vs AZT

d4T showed no clear difference in severe adverse events compared with AZT (low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 1.17 [0.97, 1.4]
  9 studies · 1363 participants
  Low

d4T vs AZT

d4T showed no clear difference in virologic response compared with AZT (low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 1.03 [0.88, 1.19]
  12 studies · 2157 participants
  Low

d4T vs AZT

d4T showed no clear difference in adherence/tolerability/retention compared with AZT (low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 0.94 [0.84, 1.05]
  12 studies · 2157 participants
  Low

d4T vs AZT

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1537 participants
  Low

d4T vs AZT

It is very uncertain whether d4T changes drug resistance compared with AZT (very low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 0.66 [0.25, 1.73]
  1 study · 174 participants
  Very low

TDF vs AZT

TDF showed no clear difference in serious adverse events compared with AZT (high certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 0.92 [0.6, 1.43]
  2 studies · 586 participants
  High

TDF vs AZT

TDF showed no clear difference in virologic response compared with AZT (high certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 2.04 [0.17, 24.84]
  2 studies · 586 participants
  High

TDF vs AZT

TDF probably leads to higher adherence/tolerability/retention compared with AZT (moderate certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 1.17 [1.06, 1.29]
  2 studies · 586 participants
  Moderate

TDF vs AZT

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 515 participants
  Moderate